Abstract
The alpha-emitting radionuclide Ra-223 is used in nuclear medicine in form of the commercially available radiopharmaceutical “Xofigo”. The direct progeny of Ra-223 is Rn-219, a noble gas with a half-life of approx. four seconds, that might be exhaled by patients treated with Ra-223. For assessing the exhalation of Rn-219, a radon monitor calibrated for this isotope is necessary. This work investigates on the response of the commercially available Alphaguard radon monitor to Rn-219 and proposes for the first time a factor for the calculation of the Rn-219-concentration in the instrument's measurement chamber from the instrument reading suitable for estimating patients exhalations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
